What is the current Price Target for the Denali Therapeutics Inc. stock?

The average Denali Therapeutics Inc. target price is $36.63. This is 166.56% higher than the current stock price. The highest price target is 482.24%, the lowest is 74.67%. 16 Analysts have issued a price target Denali Therapeutics Inc. 2026 .

How high will the Denali Therapeutics Inc. stock rise?

No reliable answer can be given as to how high the Denali Therapeutics Inc. stock will rise. The performance of stocks, including the Denali Therapeutics Inc. stock, depends on a variety of factors, such as the general economic situation, the company's business results, investor expectations and global events.

What's going on with the Denali Therapeutics Inc. stock today?

The performance of Denali Therapeutics Inc. stock on any given day can be influenced by various factors, such as market conditions, industry trends, company news and global events.

Why did the Denali Therapeutics Inc. stock fall?

The decline in Denali Therapeutics Inc. stock may be due to a variety of factors, such as market conditions, industry trends, company news, macroeconomic events or changes in investor expectations. It is important to note that stock markets are inherently volatile and the performance of an individual stock on any given day is not necessarily indicative of its long-term performance.

What is a price target?

A price target is an estimate by an analyst or investment bank of where a company's stock price could be in a certain period of time, usually 12 months.

Denali Therapeutics Inc. Forecast, price target & analysts

$12.77

7.06% today

Nasdaq, Apr 03, 06:46 pm CET

ISIN

US24823R1059

Symbol

DNLI

Reports

Quarter | Annual

Index

NASDAQ Composite

Sector

Health

Industry

Biotechnology

Overview Dividends Analysts Charts News Strategies

Denali Therapeutics Inc. Target price 2025 - Analyst rating & recommendation

Denali Therapeutics Inc. Classifications & Recommendation:

Buy

95%

Hold

Denali Therapeutics Inc. Price Target

Target Price	$36.63
Price	$13.74
Potential	166.56% register free of charge
Number of Estimates	16

	16 Analysts have issued a price target Denali Therapeutics Inc. 2026 . The average Denali Therapeutics Inc. target price is $36.63. This is 166.56% register free of charge higher than the current stock price. The highest price target is $80.00 482.24% register free of charge , the lowest is $24.00 74.67% register free of charge .
	A rating was issued by 19 analysts: 18 Analysts recommend Denali Therapeutics Inc. to buy, 1 to hold and 0 to sell.
	Analysts don't have a crystal ball either, but they do represent the opinion of the market quite well. You should not take the price potential and the ratings as a recommendation to act. Rather, they serve as an additional building block for your own opinion or stock analysis.
	Analyst Estimates: Analysts believe that the Denali Therapeutics Inc. stock has an average upside potential 2026 of 166.56% register free of charge . Most analysts recommend the Denali Therapeutics Inc. stock at Purchase.

Earnings per share, P/E ratio and EV/sales Estimates 2025, 2026 to 2029

Create a premium account to unlock analyst estimates. Learn more

Quarter Annually

	Dec '24	2025 Estimates
Earnings Per Share $	-2.57	-2.90
	142.45%	12.84%
P/E		negative
EV/Sales		37.13

17 Analysts have issued a Denali Therapeutics Inc. forecast for earnings per share. The average Denali Therapeutics Inc. EPS is

Unlock

. This is

Unlock

than earnings per share in the financial year 2024. The highest EPS forecast is

Unlock

, the lowest is

Unlock

This results in the following potential growth metrics and future valuations:

2024	$-2.57	142.45%
2025	$-2.90 12.84% Unlock
2026	$-2.58 11.03% Unlock
2027	$-2.07 19.77% Unlock
2028	$-0.71 65.70% Unlock
2029	$0.65 191.55% Unlock

Current	-5.34	71.66%
2025	-4.74 11.24% Unlock
2026	-5.32 12.24% Unlock
2027	-6.65 25.00% Unlock
2028	-19.28 189.92% Unlock
2029	21.07 209.28% Unlock

Denali Therapeutics Inc....

Current Denali Therapeutics Inc. Upgrades & Downgrades

Create a Premium account to unlock Upgrades/Downgrades. Learn more

Analyst	Rating	Action	Date
B of A Securities	Locked ➜ Locked	Locked	Mar 10 2025
B. Riley Securities	Locked ➜ Locked	Locked	Mar 05 2025
Oppenheimer	Locked ➜ Locked	Locked	Mar 03 2025
HC Wainwright & Co.	Locked ➜ Locked	Locked	Feb 28 2025
Deutsche Bank	Locked ➜ Locked	Locked	Feb 11 2025
Goldman Sachs	Locked ➜ Locked	Locked	Jan 28 2025
JP Morgan	Locked ➜ Locked	Locked	Jan 07 2025

Analyst Rating	Date
Locked B of A Securities: Locked ➜ Locked	Mar 10 2025
Locked B. Riley Securities: Locked ➜ Locked	Mar 05 2025
Locked Oppenheimer: Locked ➜ Locked	Mar 03 2025
Locked HC Wainwright & Co.: Locked ➜ Locked	Feb 28 2025
Locked Deutsche Bank: Locked ➜ Locked	Feb 11 2025
Locked Goldman Sachs: Locked ➜ Locked	Jan 28 2025
Locked JP Morgan: Locked ➜ Locked	Jan 07 2025

Discover more stocks with a high price target

Novo Nordisk 75.12%

Coinbase Global, Inc. 71.30%

BioNTech SE - ADR 48.29%

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

Start now